Developer docs
API playgroundTry for free, no card

Search company profiles

T&R Biofab

Full company profile

uuid003ernp

Namestring
T&R Biofab
Legal namestring
(주)티앤알바이오팹 (T&R Biofab Co., Ltd.)
Websiteurl
tnrbiofab.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

T&R Biofab (KOSDAQ: 246710, founded March 2013 in Siheung-si, South Korea) is a publicly traded regenerative medicine company that builds a vertically integrated 3D bioprinting platform spanning hardware, biomaterials, and cell processing. Its core technology stack includes the customizable 3DX Printer (up to 6 print heads, ±1μm resolution, polymer and hydrogel co-printing), proprietary preset extrusion multi-material printing, EER-based VdECM/SdECM biomaterials with 50-60% elastin content, and hiPSC-derived cell banking and processing. The product portfolio spans three primary lines: 3D-printed medical devices (TnR PSI Plus, TnR CFI, TnR Mesh, Nasal Mesh, nerve regeneration conduit) for craniomaxillofacial reconstruction; biosurgical solutions (Reproderm-gel, ADM products Reproderm/Reproderm Plus/SSenderm/Antira, powder and matrix hemostatic agents, PU foam dressings); and research-use tools (deCelluid bioink, TnR Scaffold) sold to academic and pharma customers.

The company monetizes through a hybrid model: exclusive B2B medical device distribution via B.Braun Korea (TnR CFI since 2021) and Johnson & Johnson Medical Korea (TnR PSI Plus since 2023, Asia-Pacific scope), direct sales of 3DX Printer systems to universities (POSTECH, Seoul National University, Georgia Tech), and through acquired subsidiary Blispharm (100% acquired December 2024) for cosmeceutical OEM including HA mask packs, PDRN serums, and melting films distributed via QVC Japan, domestic home shopping, and Dr. Ellie brand collaboration. Revenue mechanics combine one-time implant sales per procedure, capital equipment sales to research institutions, and higher-velocity consumer SKUs. Customer segments include university hospitals and surgical centers (primary), medical device distributors and healthcare procurement channels, pharmaceutical and cosmetics companies using organoid models for animal-test-free screening, academic and research institutions, and cosmetics brands. The company projects consolidated 2025 revenue of 300B KRW and operates with 51-100 employees across Siheung headquarters, Pangyo R&D Center, and Seoul (Sinsa) sales office. Regulatory positioning is anchored by 17,000+ TnR CFI procedures with zero adverse events, MFDS Class 4 device approvals, GMP and ISO 13485/9001 certifications, and an FDA 510(k) submission filed June 2025.

Short descriptiontext

T&R Biofab is a KOSDAQ-listed Korean regenerative medicine company that uses proprietary 3D bioprinting, ECM biomaterials, and hiPSC cell processing to manufacture patient-specific implants, biosurgical wound-care and hemostatic products, and research bioprinters sold to hospitals, distributors, and academic labs worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSiheungodong, South Korea
HQ citystring
Siheungodong
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D bioprinting systems, regenerative medicine devices, patient-specific implants, biomaterials research, biosurgical solutions
Industry5 codes
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code4 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Biological Products, (No Disgnostic Substances)2836
Product category
3D Bioprinting & Regenerative Medicine Medical Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model6 records
13D-Printed Medical Devices
TypeOne Time License
Description

Sale of FDA/MFDS-approved 3D-printed implantable medical devices including patient-specific implants (PSI Plus), craniofacial implants (CFI), orbital and nasal mesh products, and nerve regeneration conduits. Revenue is one-time per procedure/implant, with recurring volume driven by hospital adoption and surgical volume. Distributed exclusively through B.Braun Korea and Johnson & Johnson Medical Korea.

tnrbiofab.com
23D Bioprinter and Platform Sales (3DX Printer)
TypeHardware Sales
Description

Sale and installation of 3DX Printer systems to research institutions (university labs, hospital research centers). Includes hardware customization, software licensing, and technical support. One-time capital equipment sale model. Supplied to POSTECH, Seoul National University, Seoul St. Mary's Hospital, and Georgia Tech.

tnrbiofab.com
3Biosurgical Solutions (Wound Care & Hemostats)
TypeOne Time License
Description

Sale of VdECM-based wound dressings (Reproderm-gel), PU foam bandages (Reprofoam, Bonofoam), antibiotic-containing wound dressings, ADM products (Reproderm Plus, SSenderm, Antira), and powder/matrix-type hemostatic compounds. Both hospital-direct supply and export channels. Pursuing import substitution in ~2,700B KRW domestic hemostat market.

tnrbiofab.com
4Functional Cosmeceuticals & OEM
TypeHardware Sales
Description

Revenue from K-beauty functional cosmetic products including melting HA mask packs, HA films, and PDRN serums. Manufactured via acquired subsidiary Blispharm (100% acquired Dec 2024) and sold through QVC Japan, domestic home shopping, and export contracts. Collaborations with Dr. Ellie Byun's global beauty brand. Estimated to contribute 30%+ of projected 300B KRW revenue in 2025.

tnrbiofab.com
5hiPSC-Based Cell Therapy & Cell Banking
TypeLicensing Royalties
Description

Revenue from commercial cell bank products derived from 50 FDA-compliant human donors (skin, blood, adipose tissue). Sales of induced pluripotent stem cell-derived cardiomyocytes (iPSC licenses from Academia Japan, licensed 2020). Future revenue anticipated from GMP-grade clinical stem cell banking services and proprietary cell therapy pipeline.

tnrbiofab.com
6Bioink and Biomaterial Reagents
TypeSubscription Recurring
Description

Sale of deCelluid™ bioink and research-grade TnR Scaffold products to academic and industrial research customers. Recurring revenue from reagent and consumable supplies to research institutions operating 3DX Printer systems.

tnrbiofab.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 18 records shown
1TnR PSI Plus / T&R PSI Plus
Description

Patient-specific 3D-printed biodegradable implant for craniomaxillofacial reconstruction

tnrbiofab.com
+17 more records
Core offering1 text field

T&R Biofab develops and manufactures 3D-bioprinted medical devices, biomaterials, and bioprinting platforms for regenerative medicine. Its portfolio includes patient-specific craniofacial implants (TnR PSI Plus, CFI, Mesh, Nasal Mesh), VdECM-based biosurgical wound-care solutions (Reproderm-gel and the ADM product line), the 3DX bioprinting system, and the deCelluid bioink, sold to hospitals, medical-device distributors, and research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 17,000+ skull implant procedures completed with zero adverse events reported (as of June 2025)
+4 more records
Product overview1 text field

T&R Biofab operates as a regenerative medicine company offering a platform-plus-products architecture built around its core 3D bioprinting technology. Its flagship product is the 3DX Printer — a customizable 3D bioprinting system for fabricating artificial tissues and organs — which underpins both clinical-grade medical devices and research products. The medical device portfolio includes Patient-Specific Implants (PSI Plus/VeraPor PSI Plus, TnR CFI, TnR Mesh/Mesh Plus, Nasal Mesh) for craniomaxillofacial and orthopedic reconstruction, all manufactured from biodegradable PCL and β-TCP composites via 3D bioprinting. The biosurgical solutions line includes Reproderm-gel (topical hydrogel wound dressing with VdECM), ADM products (Reproderm Plus/Reproderm/SSenderm/Antira), and complex hemostatic agents (powder and matrix types) targeting the domestic hemostatic market. R&D pipeline products include nerve regeneration conduits, drug-delivery hydrogels, and organoid models (artificial skin, artificial liver). The company also commercializes deCelluid™ bioink for research use and, following the acquisition of BlissPack, expanded into functional cosmetics (HA-based products).

Product and service1 record
1TnR PSI Plus (VeraPor PSI Plus)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
1UNIST / Seoul Asan Hospital / et al.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-31
Description

Korean research consortium including UNIST, Seoul Asan Hospital, and T&R Biofab developing patient-customized tumor organoids for personalized medicine applications.

tnrbiofab.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

MOU signed June 2021 for joint development of hair loss treatment products combining T&R Biofab's biomaterial technology with EpiBioTech's research.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-12-01
Description

100% acquisition of Blispharm completed December 2024. Blispharm is a cosmeceutical OEM specialist with recognized production capabilities. Enables T&R Biofab's entry into functional cosmetics manufacturing and K-beauty global market with products including HA films, PDRN serums, and melting mask packs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-08
Description

Strategic partnership signed November 8, 2024 at CIIE Shanghai for China market. Joint product development and manufacturing for Chinese market demand. Hualun is a healthcare subsidiary of Chinese state-owned enterprise Hualun Group, partnering with global companies including J&J, Pfizer, Novo Nordisk, and Integra.

5CoseMAX BT Inc. (코스맥스 비티아이)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Joint research partner for development of 3D bioprinted full-thickness skin model with rete ridge structure. Research published in International Journal of Bioprinting 2024.

tnrbiofab.com
6Hwarang Cosmetics (에삐오)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Supply contract signed with Korean cosmeceutical company 에삐오 (brand: Bonotox) for Melting HA cosmetic mask pack. First supply contract for T&R Biofab's functional cosmeceutical products.

tnrbiofab.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-01-01
Description

Collaboration with US celebrity and beauty entrepreneur Dr. Ellie Byun for global marketing and sales of T&R Biofab's functional cosmeceutical products under her dr.ellie brand.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-02-01
Description

Exclusive supply contract for TnR PSI Plus (patient-specific 3D-printed implants) signed February 2023. Johnson & Johnson distributes the products across Asia-Pacific and Oceania markets. This is a flagship distribution partnership for T&R Biofab's highest-profile medical device product line.

9Ilyeon Pharmaceutical (이연제약)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-01
Description

MOU signed October 2022 for joint development of complex hemostatic medical device. Matrix-type product received MFDS Class 4 approval July 2025. Combines T&R Biofab's ECM technology with Ilyeon Pharmaceutical's thrombin for a differentiated hemostatic product targeting the 2,700B KRW domestic market.

tnrbiofab.com
10Neopharm
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-09-01
Description

Supply contract signed September 2022 for wound covering materials (창상피복재) distribution.

tnrbiofab.com
11Johnson & Johnson Mentor Worldwide LLC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

Strategic joint research agreement signed June 2022 for the development of 3D bioprinting scaffold technology for tissue reconstruction. Builds on an earlier joint research agreement with Johnson & Johnson Medical Ethicon from February 2020.

tnrbiofab.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Distribution of dental 3D printing product (absorbable membrane) through MegaGen Implant since 2019.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-04-01
Description

Supply and distribution agreement for TnR CranioFacial Implants (CFI). Launched April 2021. Used in 67 hospitals by June 2022. FDA submission for US market filed June 2025. B.Braun is a leading global medical solutions company.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-08-01
Description

License agreement signed August 2020 for iPSC-based cardiomyocyte production technology. T&R Biofab acquired sales rights for commercial cell products. Enables proprietary cell therapy development using induced pluripotent stem cells.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-01
Description

Contract from April 2020 to December 2021 to collect clinical information and biological samples (skin, blood, adipose tissue) from 50 donors under 40 years old, meeting US FDA standards. Successfully completed, enabling T&R Biofab's commercial cell bank. Both IRB-approved and FDA-compliant.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-08-01
Description

Global distribution agreement for bioink products through Merck's life science distribution network, enabling international reach for T&R Biofab's deCelluid bioink product.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-07-01
Description

Collaboration signed June 2018 for development of cell therapy products combining CHA's stem cell technology with T&R Biofab's 3D bioprinting platform.

18Busan National University Hospital (부산대학교병원)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-04-01
Description

MOU signed April 2018 for commercialization of enhanced blood vessel stem cell therapy products combining hospital's cell therapy research with T&R Biofab's 3D bioprinting technology.

tnrbiofab.com
19POSTECH (Pohang University of Science and Technology) / 포항공과대학교 산학협력단
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-06-01
Description

Open Innovation Center opened at POSTECH in June 2016. Patent transfer agreement signed September 2014. Ongoing joint research producing publications in Nature Communications (2019), Advanced Materials (2021), and Small (2020). POSTECH is a key academic partner for T&R Biofab's R&D capabilities.

tnrbiofab.com
20Seoul St. Mary's Hospital (서울성모병원)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-03-01
Description

3D Printing-based Clinical Center opened March 2016. First clinical application of scaffolds in September 2014. Joint research on 3D bioprinted liver organoids (Advanced Materials 2021). Primary clinical partner for medical device testing and validation.

tnrbiofab.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

T&R Biofab

3D Bioprinting & Regenerative Medicine Medical Devicestnrbiofab.com

T&R Biofab is a KOSDAQ-listed Korean regenerative medicine company that uses proprietary 3D bioprinting, ECM biomaterials, and hiPSC cell processing to manufacture patient-specific implants, biosurgical wound-care and hemostatic products, and research bioprinters sold to hospitals, distributors, and academic labs worldwide.

What T&R Biofab does

T&R Biofab (KOSDAQ: 246710, founded March 2013 in Siheung-si, South Korea) is a publicly traded regenerative medicine company that builds a vertically integrated 3D bioprinting platform spanning hardware, biomaterials, and cell processing. Its core technology stack includes the customizable 3DX Printer (up to 6 print heads, ±1μm resolution, polymer and hydrogel co-printing), proprietary preset extrusion multi-material printing, EER-based VdECM/SdECM biomaterials with 50-60% elastin content, and hiPSC-derived cell banking and processing. The product portfolio spans three primary lines: 3D-printed medical devices (TnR PSI Plus, TnR CFI, TnR Mesh, Nasal Mesh, nerve regeneration conduit) for craniomaxillofacial reconstruction; biosurgical solutions (Reproderm-gel, ADM products Reproderm/Reproderm Plus/SSenderm/Antira, powder and matrix hemostatic agents, PU foam dressings); and research-use tools (deCelluid bioink, TnR Scaffold) sold to academic and pharma customers.

The company monetizes through a hybrid model: exclusive B2B medical device distribution via B.Braun Korea (TnR CFI since 2021) and Johnson & Johnson Medical Korea (TnR PSI Plus since 2023, Asia-Pacific scope), direct sales of 3DX Printer systems to universities (POSTECH, Seoul National University, Georgia Tech), and through acquired subsidiary Blispharm (100% acquired December 2024) for cosmeceutical OEM including HA mask packs, PDRN serums, and melting films distributed via QVC Japan, domestic home shopping, and Dr. Ellie brand collaboration. Revenue mechanics combine one-time implant sales per procedure, capital equipment sales to research institutions, and higher-velocity consumer SKUs. Customer segments include university hospitals and surgical centers (primary), medical device distributors and healthcare procurement channels, pharmaceutical and cosmetics companies using organoid models for animal-test-free screening, academic and research institutions, and cosmetics brands. The company projects consolidated 2025 revenue of 300B KRW and operates with 51-100 employees across Siheung headquarters, Pangyo R&D Center, and Seoul (Sinsa) sales office. Regulatory positioning is anchored by 17,000+ TnR CFI procedures with zero adverse events, MFDS Class 4 device approvals, GMP and ISO 13485/9001 certifications, and an FDA 510(k) submission filed June 2025.

T&R Biofab firmographics

Firmographics
Name
T&R Biofab
Legal name
(주)티앤알바이오팹 (T&R Biofab Co., Ltd.)
Website
https://tnrbiofab.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
T&R Biofab is a KOSDAQ-listed Korean regenerative medicine company that uses proprietary 3D bioprinting, ECM biomaterials, and hiPSC cell processing to manufacture patient-specific implants, biosurgical wound-care and hemostatic products, and research bioprinters sold to hospitals, distributors, and academic labs worldwide.
Ownership category
akta.pro rank

T&R Biofab industry classification

Industry
Product category
3D Bioprinting & Regenerative Medicine Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • 3D bioprinting systems
  • Regenerative medicine devices
  • Patient-specific implants
  • Biomaterials research
  • Biosurgical solutions

Where T&R Biofab is headquartered

Location

Headquarters

HQ city
Siheungodong
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

T&R Biofab business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. 3D-Printed Medical Devices: Sale of FDA/MFDS-approved 3D-printed implantable medical devices including patient-specific implants (PSI Plus), craniofacial implants (CFI), orbital and nasal mesh products, and nerve regeneration conduits. Revenue is one-time per procedure/implant, with recurring volume driven by hospital adoption and surgical volume. Distributed exclusively through B.Braun Korea and Johnson & Johnson Medical Korea.
  2. 3D Bioprinter and Platform Sales (3DX Printer): Sale and installation of 3DX Printer systems to research institutions (university labs, hospital research centers). Includes hardware customization, software licensing, and technical support. One-time capital equipment sale model. Supplied to POSTECH, Seoul National University, Seoul St. Mary's Hospital, and Georgia Tech.
  3. Biosurgical Solutions (Wound Care & Hemostats): Sale of VdECM-based wound dressings (Reproderm-gel), PU foam bandages (Reprofoam, Bonofoam), antibiotic-containing wound dressings, ADM products (Reproderm Plus, SSenderm, Antira), and powder/matrix-type hemostatic compounds. Both hospital-direct supply and export channels. Pursuing import substitution in ~2,700B KRW domestic hemostat market.
  4. Functional Cosmeceuticals & OEM: Revenue from K-beauty functional cosmetic products including melting HA mask packs, HA films, and PDRN serums. Manufactured via acquired subsidiary Blispharm (100% acquired Dec 2024) and sold through QVC Japan, domestic home shopping, and export contracts. Collaborations with Dr. Ellie Byun's global beauty brand. Estimated to contribute 30%+ of projected 300B KRW revenue in 2025.
  5. hiPSC-Based Cell Therapy & Cell Banking: Revenue from commercial cell bank products derived from 50 FDA-compliant human donors (skin, blood, adipose tissue). Sales of induced pluripotent stem cell-derived cardiomyocytes (iPSC licenses from Academia Japan, licensed 2020). Future revenue anticipated from GMP-grade clinical stem cell banking services and proprietary cell therapy pipeline.
  6. Bioink and Biomaterial Reagents: Sale of deCelluid™ bioink and research-grade TnR Scaffold products to academic and industrial research customers. Recurring revenue from reagent and consumable supplies to research institutions operating 3DX Printer systems.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

T&R Biofab product offering

Product offering

Core offering

T&R Biofab develops and manufactures 3D-bioprinted medical devices, biomaterials, and bioprinting platforms for regenerative medicine. Its portfolio includes patient-specific craniofacial implants (TnR PSI Plus, CFI, Mesh, Nasal Mesh), VdECM-based biosurgical wound-care solutions (Reproderm-gel and the ADM product line), the 3DX bioprinting system, and the deCelluid bioink, sold to hospitals, medical-device distributors, and research institutions.

Product overview

T&R Biofab operates as a regenerative medicine company offering a platform-plus-products architecture built around its core 3D bioprinting technology. Its flagship product is the 3DX Printer — a customizable 3D bioprinting system for fabricating artificial tissues and organs — which underpins both clinical-grade medical devices and research products. The medical device portfolio includes Patient-Specific Implants (PSI Plus/VeraPor PSI Plus, TnR CFI, TnR Mesh/Mesh Plus, Nasal Mesh) for craniomaxillofacial and orthopedic reconstruction, all manufactured from biodegradable PCL and β-TCP composites via 3D bioprinting. The biosurgical solutions line includes Reproderm-gel (topical hydrogel wound dressing with VdECM), ADM products (Reproderm Plus/Reproderm/SSenderm/Antira), and complex hemostatic agents (powder and matrix types) targeting the domestic hemostatic market. R&D pipeline products include nerve regeneration conduits, drug-delivery hydrogels, and organoid models (artificial skin, artificial liver). The company also commercializes deCelluid™ bioink for research use and, following the acquisition of BlissPack, expanded into functional cosmetics (HA-based products).

Differentiator

Problem solved

Functional benefit

Brands

  • TnR PSI Plus / T&R PSI Plus: Patient-specific 3D-printed biodegradable implant for craniomaxillofacial reconstruction
  • 3DX Printer
  • Reproderm-gel
  • Reproderm / REPRODERM
  • Reproderm Plus / REPRODERM PLUS
  • SSENDERM / 쎈덤
  • ANTIRA / 안티라
  • TnR Mesh / TnR Mesh Plus
  • Nasal Mesh / 티앤알나잘메쉬
  • TnR CFI (CranioFacial Implant)
  • Nerve Regeneration Conduit
  • OS inject
  • Matrix Type Hemostatic Agent
  • Powder Type Hemostatic Agent
  • Reprofoam / Reprofoam Band
  • Bonofoam / 보노폼
  • deCelluid™
  • TnR Scaffold

Products and services

  • TnR PSI Plus (VeraPor PSI Plus)

Quantifiable outcome

  • 17,000+ skull implant procedures completed with zero adverse events reported (as of June 2025)
  • +4 more outcomes

Companies that use T&R Biofab

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles5 records

T&R Biofab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

T&R Biofab partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered minor and core.

  • UNIST / Seoul Asan Hospital / et al.minorStrategic or Co-development Partner · 31 March 2025Korean research consortium including UNIST, Seoul Asan Hospital, and T&R Biofab developing patient-customized tumor organoids for personalized medicine applications.
  • EpiBioTech (에피바이오텍)minorStrategic or Co-development Partner · 1 January 2025MOU signed June 2021 for joint development of hair loss treatment products combining T&R Biofab's biomaterial technology with EpiBioTech's research.
  • Blispharm (블리스팩)coreOEM/ Whitelabel/ Licensing Partner · 1 December 2024100% acquisition of Blispharm completed December 2024. Blispharm is a cosmeceutical OEM specialist with recognized production capabilities. Enables T&R Biofab's entry into functional cosmetics manufacturing and K-beauty global market with products including HA films, PDRN serums, and melting mask packs.
  • Hualun Pharmaceutical Commercial Group (화룬의약상업그룹유한회사)coreStrategic or Co-development Partner · 8 November 2024Strategic partnership signed November 8, 2024 at CIIE Shanghai for China market. Joint product development and manufacturing for Chinese market demand. Hualun is a healthcare subsidiary of Chinese state-owned enterprise Hualun Group, partnering with global companies including J&J, Pfizer, Novo Nordisk, and Integra.
  • CoseMAX BT Inc. (코스맥스 비티아이)minorStrategic or Co-development Partner · 1 January 2024Joint research partner for development of 3D bioprinted full-thickness skin model with rete ridge structure. Research published in International Journal of Bioprinting 2024.
  • Hwarang Cosmetics (에삐오)minorChannel Partner/ Reseller/ Distributor · 1 January 2024Supply contract signed with Korean cosmeceutical company 에삐오 (brand: Bonotox) for Melting HA cosmetic mask pack. First supply contract for T&R Biofab's functional cosmeceutical products.
  • Dr. Ellie (Ellie Byun)minorGTM or Marketing Partner · 1 January 2024Collaboration with US celebrity and beauty entrepreneur Dr. Ellie Byun for global marketing and sales of T&R Biofab's functional cosmeceutical products under her dr.ellie brand.
  • Johnson & Johnson Medical Korea (한국존슨앤드존슨메디칼)coreChannel Partner/ Reseller/ Distributor · 1 February 2023Exclusive supply contract for TnR PSI Plus (patient-specific 3D-printed implants) signed February 2023. Johnson & Johnson distributes the products across Asia-Pacific and Oceania markets. This is a flagship distribution partnership for T&R Biofab's highest-profile medical device product line.
  • Ilyeon Pharmaceutical (이연제약)coreStrategic or Co-development Partner · 1 October 2022MOU signed October 2022 for joint development of complex hemostatic medical device. Matrix-type product received MFDS Class 4 approval July 2025. Combines T&R Biofab's ECM technology with Ilyeon Pharmaceutical's thrombin for a differentiated hemostatic product targeting the 2,700B KRW domestic market.
  • NeopharmminorChannel Partner/ Reseller/ Distributor · 1 September 2022Supply contract signed September 2022 for wound covering materials (창상피복재) distribution.
  • Johnson & Johnson Mentor Worldwide LLCcoreStrategic or Co-development Partner · 1 June 2022Strategic joint research agreement signed June 2022 for the development of 3D bioprinting scaffold technology for tissue reconstruction. Builds on an earlier joint research agreement with Johnson & Johnson Medical Ethicon from February 2020.
  • MegaGen Implant (메가젠임플란트)minorChannel Partner/ Reseller/ Distributor · 1 January 2022Distribution of dental 3D printing product (absorbable membrane) through MegaGen Implant since 2019.
  • B.Braun Korea (비브라운코리아)coreChannel Partner/ Reseller/ Distributor · 1 April 2021Supply and distribution agreement for TnR CranioFacial Implants (CFI). Launched April 2021. Used in 67 hospitals by June 2022. FDA submission for US market filed June 2025. B.Braun is a leading global medical solutions company.
  • Academia Japan Inc. (Japan iPSC licensing)coreOEM/ Whitelabel/ Licensing Partner · 1 August 2020License agreement signed August 2020 for iPSC-based cardiomyocyte production technology. T&R Biofab acquired sales rights for commercial cell products. Enables proprietary cell therapy development using induced pluripotent stem cells.
  • Kyungpook National University Hospital & Chilgok Kyungpook National University Hospital (경북대학교병원, 칠곡경북대학교병원)coreStrategic or Co-development Partner · 1 April 2020Contract from April 2020 to December 2021 to collect clinical information and biological samples (skin, blood, adipose tissue) from 50 donors under 40 years old, meeting US FDA standards. Successfully completed, enabling T&R Biofab's commercial cell bank. Both IRB-approved and FDA-compliant.
  • Merck (밀리포어시그마)minorChannel Partner/ Reseller/ Distributor · 1 August 2018Global distribution agreement for bioink products through Merck's life science distribution network, enabling international reach for T&R Biofab's deCelluid bioink product.
  • CHA-Biotech (차바이오텍)minorStrategic or Co-development Partner · 1 July 2018Collaboration signed June 2018 for development of cell therapy products combining CHA's stem cell technology with T&R Biofab's 3D bioprinting platform.
  • Busan National University Hospital (부산대학교병원)minorStrategic or Co-development Partner · 1 April 2018MOU signed April 2018 for commercialization of enhanced blood vessel stem cell therapy products combining hospital's cell therapy research with T&R Biofab's 3D bioprinting technology.
  • POSTECH (Pohang University of Science and Technology) / 포항공과대학교 산학협력단coreStrategic or Co-development Partner · 1 June 2016Open Innovation Center opened at POSTECH in June 2016. Patent transfer agreement signed September 2014. Ongoing joint research producing publications in Nature Communications (2019), Advanced Materials (2021), and Small (2020). POSTECH is a key academic partner for T&R Biofab's R&D capabilities.
  • Seoul St. Mary's Hospital (서울성모병원)coreStrategic or Co-development Partner · 1 March 20163D Printing-based Clinical Center opened March 2016. First clinical application of scaffolds in September 2014. Joint research on 3D bioprinted liver organoids (Advanced Materials 2021). Primary clinical partner for medical device testing and validation.

Scale indicators11 records

Recent moves8 records

Expansion highlights3 records

T&R Biofab competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

T&R Biofab social profiles

Digital presence

T&R Biofab compliance and trust

Trust signal

Compliance6 records

T&R Biofab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

T&R Biofab leadership team

Management profile

Number of profiles

Profiles3 records

T&R Biofab subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

T&R Biofab funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

T&R Biofab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T&R Biofab

What does T&R Biofab do?

T&R Biofab develops and manufactures 3D-bioprinted medical devices, biomaterials, and bioprinting platforms for regenerative medicine. Its portfolio includes patient-specific craniofacial implants (TnR PSI Plus, CFI, Mesh, Nasal Mesh), VdECM-based biosurgical wound-care solutions (Reproderm-gel and the ADM product line), the 3DX bioprinting system, and the deCelluid bioink, sold to hospitals, medical-device distributors, and research institutions.

Is T&R Biofab a public or private company?

T&R Biofab is a public company. It is classified as public and is currently operating.

When was T&R Biofab founded?

T&R Biofab was founded in 2013. It employs 11 to 50 people.

Where is T&R Biofab based?

T&R Biofab is headquartered in Siheungodong, South Korea, in the Asia region.

How does T&R Biofab make money?

Six revenue lines are on record. 3D-Printed Medical Devices are the primary driver. The others are 3D Bioprinter and Platform Sales (3DX Printer), biosurgical Solutions (Wound Care & Hemostats), functional Cosmeceuticals & OEM, hiPSC-Based Cell Therapy & Cell Banking and bioink and Biomaterial Reagents.

Does T&R Biofab have an API?

No public API is recorded for T&R Biofab.

What industry is T&R Biofab in?

T&R Biofab's product category is 3D Bioprinting & Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication, with a secondary code of IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
3dprintAM Pulse Asia: 6,500-Printer Farm Leads APAC Manufacturing Expansion - 3DPrint.comMultiple companies across the Asia-Pacific region announced significant expansions and regulatory milestones in additive manufacturing during early August, including Jinshi Huina's planned 6,500-printer farm in China and T&R Biofab's FDA clearance for cranial implants. Key developments also involved Lohia Aerospace investing in Massivit technology in India and AML3D joining the AUKUS qualification program in Australia. These events highlight rapid industrial scaling and international market entry for 3D printing technologies.VenturesquareMakes the heart beat again… T&R Biofab secures a patent for high-purity cardiomyocyte purification technology.T&R Biofab registered a domestic patent for a method to purify and manufacture ventricular cardiomyocytes from iPSC-based cell therapies. The technology uses surface markers to isolate only ventricular cells, aiming to improve cell purity and enable mass production. The company plans to combine it with 3D bioprinting and ECM technologies for heart tissue regeneration products.VenturesquareT&R Biofab reduces its deficit margin... Performance rebounds due to growth in ECM bio-surgical and cosmetics.T&R Biofab reported Q1 revenue of 87.2 billion won, up 46% year-on-year, with operating loss narrowing to 930 million won and net loss to 1.66 billion won. The growth was driven by ECM-based biosurgical products and freeze-dried ball cosmetics, while subsidiary Blisspack sales rose 42%.PR NewswireCJ Foods Partners with T&R Biofab to Shape the Future of FoodCJ Foods and T&R Biofab signed a joint development agreement to create alternative meat using 3D bioprinting technology. The plant-based food market is projected to reach $162 billion by 2030, and the collaboration aims to improve taste, texture, and nutrition. CJ Foods plans to invest in sustainable food technologies.